620 related articles for article (PubMed ID: 30999964)
1. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
Bol KF; Schreibelt G; Rabold K; Wculek SK; Schwarze JK; Dzionek A; Teijeira A; Kandalaft LE; Romero P; Coukos G; Neyns B; Sancho D; Melero I; de Vries IJM
J Immunother Cancer; 2019 Apr; 7(1):109. PubMed ID: 30999964
[TBL] [Abstract][Full Text] [Related]
2. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.
Tel J; Schreibelt G; Sittig SP; Mathan TS; Buschow SI; Cruz LJ; Lambeck AJ; Figdor CG; de Vries IJ
Blood; 2013 Jan; 121(3):459-67. PubMed ID: 23212525
[TBL] [Abstract][Full Text] [Related]
3. Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy.
Schreibelt G; Duiveman-de Boer T; Pots JM; van Oorschot TGM; de Boer AJ; Scharenborg NM; van de Rakt MWMM; Bos K; de Goede AL; Petry K; Brüning M; Angerer C; Schöggl C; Dzionek A; de Vries IJM
Methods Cell Biol; 2024; 183():33-50. PubMed ID: 38548417
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy.
Schreibelt G; Tel J; Sliepen KH; Benitez-Ribas D; Figdor CG; Adema GJ; de Vries IJ
Cancer Immunol Immunother; 2010 Oct; 59(10):1573-82. PubMed ID: 20204387
[TBL] [Abstract][Full Text] [Related]
5. Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c
Lu Y; Xu W; Gu Y; Chang X; Wei G; Rong Z; Qin L; Chen X; Zhou F
Front Immunol; 2019; 10():2829. PubMed ID: 31921114
[TBL] [Abstract][Full Text] [Related]
6. Potential approaches for more successful dendritic cell-based immunotherapy.
Chiang CL; Balint K; Coukos G; Kandalaft LE
Expert Opin Biol Ther; 2015 Apr; 15(4):569-82. PubMed ID: 25553913
[TBL] [Abstract][Full Text] [Related]
7. Acute aerobic exercise induces a preferential mobilisation of plasmacytoid dendritic cells into the peripheral blood in man.
Brown FF; Campbell JP; Wadley AJ; Fisher JP; Aldred S; Turner JE
Physiol Behav; 2018 Oct; 194():191-198. PubMed ID: 29763678
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy.
Bakdash G; Schreurs I; Schreibelt G; Tel J
Expert Rev Clin Immunol; 2014 Jul; 10(7):915-26. PubMed ID: 24758519
[TBL] [Abstract][Full Text] [Related]
9. Increased tubulointerstitial recruitment of human CD141(hi) CLEC9A(+) and CD1c(+) myeloid dendritic cell subsets in renal fibrosis and chronic kidney disease.
Kassianos AJ; Wang X; Sampangi S; Muczynski K; Healy H; Wilkinson R
Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1391-401. PubMed ID: 24049150
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.
Boudewijns S; Bloemendal M; Gerritsen WR; de Vries IJ; Schreibelt G
Hum Vaccin Immunother; 2016 Oct; 12(10):2523-2528. PubMed ID: 27322496
[TBL] [Abstract][Full Text] [Related]
11. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.
Jongbloed SL; Kassianos AJ; McDonald KJ; Clark GJ; Ju X; Angel CE; Chen CJ; Dunbar PR; Wadley RB; Jeet V; Vulink AJ; Hart DN; Radford KJ
J Exp Med; 2010 Jun; 207(6):1247-60. PubMed ID: 20479116
[TBL] [Abstract][Full Text] [Related]
12. Plasmacytoid Dendritic Cells and Cancer Immunotherapy.
Fu C; Zhou L; Mi QS; Jiang A
Cells; 2022 Jan; 11(2):. PubMed ID: 35053338
[TBL] [Abstract][Full Text] [Related]
13. Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.
Wimmers F; Schreibelt G; Sköld AE; Figdor CG; De Vries IJ
Front Immunol; 2014; 5():165. PubMed ID: 24782868
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis.
Cooles FAH; Anderson AE; Skelton A; Pratt AG; Kurowska-Stolarska MS; McInnes I; Hilkens CMU; Isaacs JD
Front Immunol; 2018; 9():755. PubMed ID: 29867920
[TBL] [Abstract][Full Text] [Related]
15. Case Report:
Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
Front Immunol; 2021; 12():752563. PubMed ID: 35003064
[TBL] [Abstract][Full Text] [Related]
16. Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation.
Sittig SP; de Vries IJM; Schreibelt G
Biomedicines; 2015 Dec; 3(4):282-303. PubMed ID: 28536413
[TBL] [Abstract][Full Text] [Related]
17. Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.
Nava S; Lisini D; Pogliani S; Dossena M; Bersano A; Pellegatta S; Parati E; Finocchiaro G; Frigerio S
Stem Cells Transl Med; 2015 Oct; 4(10):1164-72. PubMed ID: 26273063
[TBL] [Abstract][Full Text] [Related]
18. A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets.
Sittig SP; Bakdash G; Weiden J; Sköld AE; Tel J; Figdor CG; de Vries IJ; Schreibelt G
Mediators Inflamm; 2016; 2016():3605643. PubMed ID: 27057096
[TBL] [Abstract][Full Text] [Related]
19. Cellular immunotherapy with dendritic cells in cancer: current status.
Nencioni A; Brossart P
Stem Cells; 2004; 22(4):501-13. PubMed ID: 15277696
[TBL] [Abstract][Full Text] [Related]
20. Tumoricidal activity of human dendritic cells.
Tel J; Anguille S; Waterborg CE; Smits EL; Figdor CG; de Vries IJ
Trends Immunol; 2014 Jan; 35(1):38-46. PubMed ID: 24262387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
